|
Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes
|
Feb 2015
|
Eur J Haematol
|
myelodysplastic syndromes (MDS)
|
|
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience
|
Sep 2020
|
Leukemia & Lymphoma
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience
|
Aug 2017
|
Am J Hematol
|
aplastic anemia
|
|
Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis
|
May 2018
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
|
Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes
|
Jul 2012
|
Am J Med
|
myelodysplastic syndromes (MDS)
|
|
Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update
|
Oct 2012
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.
|
Nov 2012
|
Clin Adv Hematol Oncol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry.
|
May 2013
|
Int J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
|
Dec 2014
|
J Blood Med
|
myelodysplastic syndromes (MDS)
|
|
Clofarabine in the treatment of myelodysplastic syndromes.
|
Feb 2014
|
Expert Opin Investig Drugs
|
myelodysplastic syndromes (MDS)
|
